Research. Innovation. Translation.

The Consortium for Clinical Research and Innovation, Singapore (CRIS) strengthens synergies and develops strategies for national clinical research and translation programmes that are under the stewardship of the Ministry of Health. It is a subsidiary of the Ministry of Health Holdings (MOHH).

At CRIS, we develop your career in tandem with your aspirations.

We are looking for great people who are passionate about advancing clinical research and innovation. From translational funding and strategic guidance, to scientific and operational study support, there is a role for everyone dedicated to impact change.

Join us and be part of our synergy.

About Our Programmes


The Singapore Clinical Research Institute (SCRI) was established in 2008 as the national academic clinical research organisation to enhance the standards of clinical research in Singapore. In 2021, it was appointed as the national coordinating body to implement the national clinical trial strategy and enhance clinical trial ecosystem.



Precision Health Research, Singapore (PRECISE) was established in 2020 as the central entity to coordinate a whole-of- government effort to implement Phase II of Singapore’s 10-year National Precision Medicine (NPM) strategy.



The National Health Innovation Centre Singapore (NHIC) was established in 2014 as a nationally appointed Innovation and Enterprise Office that works with Public Healthcare Institutions across Singapore to identify, develop and commercialise promising clinical innovations to benefit patients and improve healthcare delivery.



The Singapore Translational Cancer Consortium (STCC) was established in 2020 as a nationally coordinated consortium to synergise cancer research capabilities in Singapore, bringing together unmatched basic, clinical and translational talent to create globally significant peaks of excellence in selected Asian cancers.



The Advanced Cell Therapy and Research Institute, Singapore (ACTRIS) was established in 2020 to meet the increasing clinical demand of using cellular therapeutics to treat various life-threatening diseases. It facilitates the discovery, process development and manufacturing of cellular-based therapeutics across the broad spectrum of immunotherapy and regenerative medicine.



The Cardiovascular Disease National Collaborative Enterprise (CADENCE) was established in 2023 as a national clinical translational programme aimed at synergising cardiovascular research and technology capabilities across Singapore.


Search results for "". Page 1 of 1, Results 1 to 12 of 12
Requisition No. Title Date Sort descending
457 Temp Admin (Data Entry) (2 months) 15 Sep 2023
456 Medical Writer, SCRI
456 Medical Writer, SCRI 14 Sep 2023
14 Sep 2023
450 Senior/Executive, SCRI Academy 7 Sep 2023
442 Executive, Chief Scientific Officer Office 4 Sep 2023
452 Assistant/Clinical Trial Manager, STCC 31 Aug 2023
451 Project Coordinator, STCC
451 Project Coordinator, STCC 31 Aug 2023
31 Aug 2023
453 Health Economist/Epidemiologist 31 Aug 2023
443 Senior / Clinical Research Associate, SCRI 31 Aug 2023
448 Manager, Projects and Partnerships, NHIC 31 Aug 2023
455 Alliance Manger/Assistant Manager (Clinical Research) 31 Aug 2023
444 Laboratory Officer
444 Laboratory Officer 28 Aug 2023
28 Aug 2023
449 Senior/Executive, Grants, NHIC 28 Aug 2023